{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:32:28Z","timestamp":1792798348756,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["300180"],"award-info":[{"award-number":["300180"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03295-4","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T22:33:20Z","timestamp":1751841200000},"page":"4432-4446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative Effectiveness of FF\/UMEC\/VI and BUD\/GLY\/FORM in Patients with COPD Stepping Up From Dual Therapy"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9642-1261","authenticated-orcid":false,"given":"Jadwiga A.","family":"Wedzicha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-5579","authenticated-orcid":false,"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Boscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-2950","authenticated-orcid":false,"given":"Olivier","family":"Le Rouzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurita","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7151-4311","authenticated-orcid":false,"given":"Rosirene","family":"Paczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-9590","authenticated-orcid":false,"given":"Stephen","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-7673","authenticated-orcid":false,"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3646-7828","authenticated-orcid":false,"given":"David","family":"Mannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"2","key":"3295_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s12325-024-03088-1","volume":"42","author":"D Mannino","year":"2025","unstructured":"Mannino D, Weng S, Germain G, et al. Comparative effectiveness of fluticasone furoate\/umeclidinium\/vilanterol and budesonide\/glycopyrrolate\/formoterol fumarate among US patients with chronic obstructive pulmonary disease. Adv Ther. 2025;42(2):1131\u201346. https:\/\/doi.org\/10.1007\/s12325-024-03088-1.","journal-title":"Adv Ther."},{"key":"3295_CR2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2025 report. 2025. https:\/\/goldcopd.org\/2025-gold-report\/. Accessed May 16, 2025."},{"key":"3295_CR3","unstructured":"U.S. Food and Drug Administration. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol). Prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209482s018lbl.pdf. Accessed May 16, 2025."},{"key":"3295_CR4","unstructured":"U.S. Food and Drug Administration. BREZTRI AEROSPHERE\u2122 (budesonide, glycopyrrolate, and formoterol fumarate). Prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212122s000lbl.pdf. Accessed May 16, 2025."},{"key":"3295_CR5","unstructured":"European Medicines Agency. Trelegy Ellipta. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trelegy-ellipta. Accessed May 16, 2025."},{"key":"3295_CR6","unstructured":"European Medicines Agency. Trixeo Aerosphere. 2024. http:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/trixeo-aerosphere. Accessed May 16, 2025."},{"issue":"18","key":"3295_CR7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1713901.","journal-title":"N Engl J Med."},{"key":"3295_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107040","volume":"205","author":"S Bardsley","year":"2022","unstructured":"Bardsley S, Criner GJ, Halpin DMG, et al. Single-inhaler triple therapy fluticasone furoate\/umeclidinium\/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022;205:107040. https:\/\/doi.org\/10.1016\/j.rmed.2022.107040.","journal-title":"Respir Med."},{"key":"3295_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106807","volume":"197","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Wu B, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study. Respir Med. 2022;197: 106807. https:\/\/doi.org\/10.1016\/j.rmed.2022.106807.","journal-title":"Respir Med."},{"key":"3295_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/COPD.S424497","volume":"19","author":"M Bogart","year":"2024","unstructured":"Bogart M, Bengtson LGS, Johnson MG, Bunner SH, Gronroos NN, DiRocco KK. Outcomes following initiation of triple therapy with fluticasone furoate\/umeclidinium\/vilanterol versus multiple-inhaler triple therapy among medicare advantage with part D beneficiaries and those commercially enrolled for health care insurance in the United States. Int J Chron Obstruct Pulmon Dis. 2024;19:97\u2013110. https:\/\/doi.org\/10.2147\/COPD.S424497.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"issue":"1","key":"3295_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1916046.","journal-title":"N Engl J Med."},{"issue":"5","key":"3295_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553\u201364. https:\/\/doi.org\/10.1164\/rccm.202006-2618OC.","journal-title":"Am J Respir Crit Care Med."},{"issue":"10","key":"3295_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358. https:\/\/doi.org\/10.1016\/S2213-2600(18)30327-8.","journal-title":"Lancet Respir Med."},{"key":"3295_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080409","volume":"387","author":"WB Feldman","year":"2024","unstructured":"Feldman WB, Suissa S, Kesselheim AS, et al. Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. BMJ. 2024;387:e080409. https:\/\/doi.org\/10.1136\/bmj-2024-080409.","journal-title":"BMJ."},{"key":"3295_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/COPD.S173901","volume":"14","author":"S Gaduzo","year":"2019","unstructured":"Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 2019;14:391\u2013401. https:\/\/doi.org\/10.2147\/COPD.S173901.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"3295_CR16","unstructured":"Elixhauser A, Steiner C, Kruzikas D. HCUP comorbidity software. Healthcare Cost and Utilization Project (HCUP). October 2015. Agency for Healthcare Research and Quality, Rockville, MD. https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp#download. Accessed May 16, 2025."},{"issue":"9","key":"3295_CR17","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s12325-019-01015-3","volume":"36","author":"F Maltais","year":"2019","unstructured":"Maltais F, Ferguson GT, Feldman GJ, et al. A randomized, double-blind, double-dummy study of glycopyrrolate\/formoterol fumarate metered dose inhaler relative to umeclidinium\/vilanterol dry powder inhaler in COPD. Adv Ther. 2019;36(9):2434\u201349. https:\/\/doi.org\/10.1007\/s12325-019-01015-3.","journal-title":"Adv Ther."},{"issue":"2","key":"3295_CR18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s12325-024-03055-w","volume":"42","author":"C Young","year":"2025","unstructured":"Young C, Lee LY, DiRocco KK, et al. Adherence and persistence with single-inhaler triple therapy among patients with COPD using commercial and medicare advantage US health plan claims data. Adv Ther. 2025; 42(2):830\u201348. https:\/\/doi.org\/10.1007\/s12325-024-03055-w.","journal-title":"Adv Ther"},{"issue":"10","key":"3295_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/03007995.2023.2247969","volume":"39","author":"D Stolz","year":"2023","unstructured":"Stolz D, Hermansson E, Ouwens M, et al. Mortality risk reduction with budesonide\/glycopyrrolate\/formoterol fumarate versus fluticasone furoate\/umeclidinium\/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT. Curr Med Res Opin. 2023;39(10):1395\u2013405. https:\/\/doi.org\/10.1080\/03007995.2023.2247969.","journal-title":"Curr Med Res Opin."},{"issue":"9","key":"3295_CR20","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","volume":"39","author":"AS Ismaila","year":"2022","unstructured":"Ismaila AS, Haeussler K, Czira A, et al. Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis. Adv Ther. 2022;39(9):3957\u201378. https:\/\/doi.org\/10.1007\/s12325-022-02231-0.","journal-title":"Adv Ther."},{"key":"3295_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105857","volume":"161","author":"DA Mahler","year":"2020","unstructured":"Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857. https:\/\/doi.org\/10.1016\/j.rmed.2019.105857.","journal-title":"Respir Med."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03295-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:53:57Z","timestamp":1768978437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03295-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3295"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03295-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jadwiga A. Wedzicha reports grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, and Novartis, consulting fees from AstraZeneca, EpiEndo Pharmaceuticals, GSK, Gilead, Novartis, Pfizer, Roche, and Empirico, honoraria for lectures, presentations or educational events from AstraZeneca, Boehringer Ingelheim, Glenmark, GSK, Novartis, Recipharm, Roche, and Sanofi, and participation as the data safety monitoring board chair for Virtus. Stephen G. Noorduyn, Valentina Di Boscio, Anurita Majumdar, Rosirene Paczkowski, and Stephen Weng are employees of GSK and\/or hold financial equities in GSK. Stephen G. Noorduyn is also a PhD candidate at McMaster University. Olivier Le Rouzic is a principal investigator of CSL Behring and Vertex studies and reports receiving personal fees and\/or congress support from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, LFB, and Sanofi outside the submitted work. Guillaume Germain and Fran\u00e7ois Lalibert\u00e9 are employees of Groupe d\u2019analyse which received funding from GSK to conduct this study but not for manuscript development. David Mannino is a consultant for AstraZeneca, the COPD Foundation, Genentech, GSK, Regeneron, and UpToDate. David Mannino is also an expert witness on behalf of people suing the tobacco and vaping industries.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study complied with all applicable laws regarding patient privacy, as described in the Declaration of Helsinki. No direct patient contact or primary collection of individual human patient data occurred in this study. This study used existing, fully de-identified data that complied with the requirements of the Health Insurance Portability and Accountability Act and the patient(s) cannot be identified, directly or through identifiers. Study results were in tabular form and aggregate analyses that omit patient identification; therefore, informed consent and ethics committee or Institutional Review Board approval were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}